These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11761010)

  • 1. Biotechnologically manufactured drugs for inflammatory bowel disease.
    Petersen JA; Rasmussen SN
    Scand J Gastroenterol; 2001 Dec; 36(12):1233-8. PubMed ID: 11761010
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal antibody use in inflammatory bowel disease.
    Hayes CE; Cerezo CS
    Med Health R I; 2011 Nov; 94(11):337-40. PubMed ID: 22204097
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.
    Wang Y; Mao Y; Zhang J; Shi G; Cheng L; Lin Y; Li Y; Zhang X; Zhang Y; Chen X; Deng J; Su X; Dai L; Yang Y; Zhang S; Yu D; Wei Y; Deng H
    J Cell Mol Med; 2018 Feb; 22(2):1014-1025. PubMed ID: 29193791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppresive therapy for inflammatory bowel disease.
    Casis Herce B
    Rev Esp Enferm Dig; 2003 Jul; 95(7):456-8, 453-5. PubMed ID: 12952507
    [No Abstract]   [Full Text] [Related]  

  • 9. bioLOGIC Europe 2007--Terrapinn's eighth annual conference.
    Mackay J
    IDrugs; 2007 Aug; 10(8):543-8. PubMed ID: 17665328
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New cytokine therapeutics for inflammatory bowel disease.
    Stokkers PC; Hommes DW
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.
    Fiorino G; Correale C; Fries W; Repici A; Malesci A; Danese S
    Expert Rev Clin Immunol; 2010 Jul; 6(4):567-72. PubMed ID: 20594130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory peptides and proteins in inflammatory bowel disease.
    Veljaca M
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1387-94. PubMed ID: 11890353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving growth in children with inflammatory bowel disease.
    Ahmed SF; Wong JS; McGrogan P
    Horm Res; 2007; 68 Suppl 5():117-21. PubMed ID: 18174726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies target inflammatory bowel disease.
    Hampton T
    JAMA; 2004 Jul; 292(1):29-30. PubMed ID: 15238575
    [No Abstract]   [Full Text] [Related]  

  • 17. Growth hormone in inflammatory bowel disease.
    De Pascalis B; Bianchi A; Satta MA; Lupascu A; Mentella MC; Leo D; Fiore F; Fedeli P; Pontecorvi A; Pola P; Melina D; Gasbarrini A; De Marinis L; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2006; 10(1):13-6. PubMed ID: 16494105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of inflammatory bowel disease care.
    Sandborn WJ
    Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.